Coronavirus (COVID-19) Update - We are open with your safety in mind.
Click here to learn more.
The goal of this study is to evaluate the efficacy of BIIB059 in reducing disease activity in subjects with active cutaneous lupus erythematosus (CLE). The subject screening period will last up to 4 weeks. This will be followed by a treatment period of 16 weeks, with subjects randomized to 1 of 4 possible arms, all which will receive monthly treatments given in the office. Two groups will receive BIIB059 and two groups will receive the placebo. The following safety follow-up period will consist of 12 weeks of monthly visits.
Biogen MA, Inc.
Alison Ehrlich, MD, MHS/Dermatology